Quality of life, religiosity, and anxiety and depressive symptoms in liver transplantation candidates

Abstract

Objective: To evaluate quality of life, religiosity and anxiety and depressive symptoms in liver transplant candidates. Method: An epidemiological and cross-sectional study carried out with liver transplant candidates attended at the outpatient clinic of a University Hospital from 2014 to 2016. Results: Fifty (50) patients with a mean age of 52.5 years old participated in the study, predominantly male (58.0%), having access to primary education (48.0%), Model for End-Stage Liver Disease between 10-19 and having viral hepatitis as the main etiology. They presented an average quality of life score (4.1), high intrinsic religiosity index (5.6) and the presence of anxiety (52.0%) and depressive symptoms (48.0%). It was possible to observe an association between religiosity and quality of life in the worry domain, with higher non-organizational religiosity leading to higher quality of life; anxiety and depressive symptoms were not associated with quality of life and religiosity. However, patients with higher levels of education were more likely to present depressive symptoms. Conclusion: The analysis of quality of life and religiosity was significant, reinforcing the need for the care team to consider religiosity as a coping strategy for the disease.

A scoping review to identify and map the multidimensional domains of pain in adults with advanced liver disease

“…There was a wide range of male (29% 67 -98% 83 ) and female (2% 83 -71% 67 ) study participants. However, the majority of studies (34; 79%) [45][46][47][48][49][50][51][52][53][54]56,57,59,60,62,63,65,66,68,[70][71][72][73][74][75][76][77][81][82][83][84][85][86][87] had higher proportions of male than female participants. The age among the participants in the studies ranged from 23 68 to 87 57 years.…”

“…The majority of studies were conducted in the United States (19; 44%). 50,52,54,56,[59][60][61][62][63]70,72,75,[80][81][82][83][84][85][86] Other study locations included Egypt (4; 9%), [45][46][47][48] Canada (2; 5%), 64,79 Italy (2; 5%), 53,57 The Netherlands (2; 5%), 68,69 Brazil (1; 2%), 77 Germany (1; 2%), 71 India (1; 2%), 51 Mexico (1; 2%), 67 Spain (1; 2%), 78 Turkey (1; 2%), 55 and the United Kingdom (1; 2%). 58 Seven (18%) studies did not report the country where the research was conducted.…”

“…58 Seven (18%) studies did not report the country where the research was conducted. 49,65,66,73,74,76,77 Study settings include inpatient (16; 37%), [45][46][47][48][50][51][52][53][54][55][56][57]59,60,79,87 outpatient (11; 26%), 58,61,63,67,70,72,75,77,82,84,85 and both in-and outpatient clinical settings (1; 2%). 76 Fifteen (35%) studies did not specify the patient setting.…”

“…76 Fifteen (35%) studies did not specify the patient setting. 49,62,[64][65][66]68,69,71,73,74,78,80,81,83,86 A majority of the studies collected patient data in a single site (22; 51%), [46][47][48][53][54][55][56][57]59,60,67,68,70,71,75,77,79,82,[84][85][86][87] and others had two 50,52,76,81 and three 45 different study locations.…”

“…For example, 1 (2%) categorized participant diagnosis as advanced liver disease. 59 Other categorizations included unspecified cirrhosis (19; 44%), [46][47][48][49][50][51]53,54,61,62,66,70,75,[77][78][79][83][84][85] disease severity classified by the Child-Pugh method (14; 33%), 46,49,[51][52][53]55,57,[59][60][61][62]66,67,75 model for end-stage liver disease (13; 30%), 50,54,56,70,73,75,[78][79][80][81][83][84][85] decompensation (2; 5%), 69,81 and end-stage liver disease (1; 2%). 80…”